IN8BIO (INAB) CEO William Ho receives 154,500 stock options at $1.58 strike

Rhea-AI Filing Summary

IN8BIO, INC. CEO William Tai-Wei Ho received an employee stock option grant covering 154,500 shares of common stock at an exercise price of $1.58 per share. The option expires on May 9, 2036 and represents compensation, not an open-market purchase.

The award vests in four equal installments of 25% each on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent on the CEO continuing to provide service through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ho William Tai-Wei

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	154,500	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 154,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 154,500 options Exercise price: $1.58 per share Options after transaction: 154,500 options +3 more

6 metrics

Option grant size 154,500 options Employee stock option award to CEO William Ho

Exercise price $1.58 per share Strike price for employee stock option grant

Options after transaction 154,500 options Total options held following reported grant

Option expiration date May 9, 2036 Expiration of employee stock option grant

First vesting date November 9, 2026 Initial 25% option vesting tranche

Final vesting date May 9, 2028 Last 25% vesting installment, subject to continued service

Key Terms

Employee Stock Option, exercise price, vesting, Common Stock, +1 more

5 terms

Employee Stock Option financial

"Employee Stock Option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

exercise price financial

"conversion_or_exercise_price: "1.5800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ho William Tai-Wei

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.58	05/09/2026		A		154,500		(1)	05/09/2036	Common Stock	154,500	$0	154,500	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IN8BIO (INAB) disclose about CEO William Ho in this Form 4?

IN8BIO reported that CEO William Tai-Wei Ho received an employee stock option grant for 154,500 shares of common stock at an exercise price of $1.58 per share, expiring on May 9, 2036, as equity-based compensation.

How many options did IN8BIO (INAB) grant to its CEO and at what price?

The CEO received 154,500 stock options, each giving the right to buy one share of IN8BIO common stock at an exercise price of $1.58 per share. These options are structured as an employee stock option award under the company’s compensation program.

What is the vesting schedule for the IN8BIO (INAB) CEO’s new stock options?

The option vests in four equal 25% installments. Vesting dates are November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, subject to William Ho’s continued service with IN8BIO through each vesting date.

Do the IN8BIO (INAB) CEO’s options from this Form 4 represent an open-market share purchase?

No. The filing describes an employee stock option grant, coded as a grant or award acquisition. It is a compensation-related derivative award, not an open-market buy or sell of existing IN8BIO common shares on the stock market.

How many stock options does the IN8BIO (INAB) CEO hold after this reported grant?

Following this transaction, William Tai-Wei Ho is shown holding 154,500 employee stock options directly. These options are exercisable into an equal number of IN8BIO common shares, subject to the vesting schedule and the stated expiration date.

When do the newly granted IN8BIO (INAB) CEO options expire?

The Form 4 states that the employee stock options granted to CEO William Ho expire on May 9, 2036. After this expiration date, any unexercised portion of the 154,500-share option award would no longer be exercisable into IN8BIO common stock.